Phathom Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Steven Basta

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Steven Basta”): 42,656,800 for, 4,490,781 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final voting results for the matters submitted to a vote of stockholders were as follows: Proposal No. 1 - Election of Class I Directors At the Annual Meeting, the Company's stockholders elected the persons listed below as Class I directors for a three-year term expiring at the Company's 2029 A…”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 52 managers: 8,860,069 for, 1,434,235 withheld, 6 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 1 managers: 1,493,854 for.

Description as filed by funds: To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Mark Stenhouse

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Mark Stenhouse”): 41,249,990 for, 5,897,591 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final voting results for the matters submitted to a vote of stockholders were as follows: Proposal No. 1 - Election of Class I Directors At the Annual Meeting, the Company's stockholders elected the persons listed below as Class I directors for a three-year term expiring at the Company's 2029 A…”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 8,307,410 for, 1,986,893 withheld, 7 abstained.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Theodore R. Schroeder

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Theodore R. Schroeder”): 42,578,532 for, 4,569,049 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final voting results for the matters submitted to a vote of stockholders were as follows: Proposal No. 1 - Election of Class I Directors At the Annual Meeting, the Company's stockholders elected the persons listed below as Class I directors for a three-year term expiring at the Company's 2029 A…”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 8,830,289 for, 1,464,015 withheld, 6 abstained.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay").

Phathom Pharmaceuticals, Inc.’s own tally for this item (“3. Approval of the Compensation of the Named Executive Officers ("say-on-pay") The Company's stockholders voted and approved, on a non-binding, advisory basis, the compensation of the named executive officers”): 44,449,761 for, 2,532,145 against, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 52 managers: 9,538,792 for, 744,572 against, 10,946 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 147 managers: 41,788,694 for, 2,143,324 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Phathom Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of Independent Registered Public Accounting Firm”): 64,482,757 for, 49,661 against — passed, per its Form 8-K filed May 21, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal 2026:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 10,288,364 for, 5,946 abstained.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.